[Secondary prevention with clopidogrel after TIA or stroke]

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Antiplatelet agents are crucial for reducing vascular complications in patients with TIA or stroke of arterial origin.
• International guidelines recommend aspirin/dipyridamole, clopidogrel monotherapy, or aspirin monotherapy post-TIA/stroke.
• Current Dutch standard is aspirin and dipyridamole combination therapy.

Purpose of the Study:

• To evaluate clopidogrel monotherapy as an alternative to aspirin and dipyridamole for secondary prevention after TIA or stroke.
• To align Dutch secondary prevention guidelines with international recommendations.

Main Methods:

• Review of international guidelines and current Dutch practices for antiplatelet therapy post-TIA/stroke.
• Comparative analysis of efficacy, usability, side effects, and cost of different antiplatelet strategies.

Main Results:

• Clopidogrel monotherapy demonstrates comparable efficacy to aspirin and dipyridamole combination therapy.
• Clopidogrel monotherapy offers advantages in terms of ease of use and a lower incidence of side effects.
• Recent cost reductions make clopidogrel monotherapy a more economically viable option.

Conclusions:

• Clopidogrel monotherapy is a recommended alternative to aspirin and dipyridamole for secondary prevention in TIA/stroke patients.
• Adherence to international guidelines for thromboprophylaxis is advised.
• Consideration of clopidogrel monotherapy is warranted as an alternative to current standard therapy.